NurExone Biologic Inc. announced the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes. Exosomes, which have a natural affinity for inflamed tissues, deliver loaded therapeutic cargo to inflamed tissues or cells, creating a healing environment. Therapeutic cargo to be delivered is expected to include different types of small molecules including miRNA, siRNA, mRNA, lncRNA, peptides or even synthetic drugs.

The Company's ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company's dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs. Scientific results and initiatives have demonstrated efficiency of the Company's large-scale production process, its effectiveness of the Company's proprietary small-interfering RNA ("siRNA") sequences as therapeutic cargo and the technology for loading therapeutic cargo into exosomes. The Company's proprietary loading technology is described in a recently published PCT application entitled "Compositions and Methods for Loading Extracellular Vesicles", WO/2023/233395.